Follow on Google News News By Tag * Drug * Disease * Pipeline * Parkinson * Clinical * Trial * Journals * Agonist * Compound * Early Stage * More Tags... Industry News News By Location Country(s) Industry News
Follow on Google News | Just Released: "Pipeline and Commercial Insight: Parkinson's Disease"Recently published research from Datamonitor, "Pipeline and Commercial Insight: Parkinson's Disease - Reformulations sustain market growth in the absence of therapeutic breakthroughs", is now available at Fast Market Research
Features and benefits * Quantify the historic (2005-09) and future (2010-19) size of the Parkinson's disease market. * Comprehensive epidemiology review of the Parkinson's disease market authored by trained epidemiologists. * Review of the current Parkinson's disease drug dynamics, including detailed profiles. * Commercial and clinical assessment of key late-stage pipeline drugs, with key opinion leader comment and region-specific sales forecasts to 2019. * Analysis of current treatment approaches, patient acquisition and clinical unmet needs. Highlights The major Parkinson's disease growth driver over the 2005-09 period was the dopamine agonist class, which accounted for nearly half the Parkinson's disease market sales, supported by the continued uptake of the newer catechol-O-methyltransferase (COMT) inhibitor and monoamine oxidase inhibitor (MAOI) classes.Parkinson's disease market growth is set to slump, as an unimpressive late-stage pipeline will fail to offset generic incursion. The US market will experience a considerable drop in market share, from 32% in 2009 to 25% in 2019, as generics take hold.New reformulations and the novel adenosine A2a receptor antagonist drugs do not offer the benefits or differentiation required to usurp traditional therapies. Your key questions answered * What are the commercial prospects of current and potential therapies for Parkinson's disease over the next 10 years? * How will the impact of recent patent expiries and new product launches affect the Parkinson's disease market? * How receptive is the market to new pipeline drugs and reformulations, in light of the availability of generic dopamine agonists? * How will the new class of adenosine A2a receptior antagonists perform in the future marketplace? * What are the current treatment approaches and unmet medical needs in Parkinson's disease? For more information or to purchase this report, go to: - http://www.fastmr.com/ Partial Table of Contents: Executive Summary Strategic scoping and focus Datamonitor insight into the disease market Related reports VERVIEW Catalyst Summary 1. PATIENT POTENTIAL Key findings Market definition for Parkinson's disease Disease definition Unmet needs in Parkinson's disease Disease-modifying therapy Efficacy in reducing motor complications Reduced non-motor side effects Reduced pill burden Delayed introduction of levodopa therapy 2. EPIDEMIOLOGY Key findings Introduction Disease definition and diagnosis criteria Global variation and temporal trends Prevalence: stable across markets Incidence: stable in time Survival: improved by treatment Mortality: decreased in the young Comorbidities of Parkinson's disease Risk factors Age: strongest risk factor Gender: more prevalent in males Genetic predisposition: Lifestyle factors: role of smoking and diet ther factors: agricultural chemicals are strong predictors Epidemiologic forecasting of Parkinson's disease Sources of epidemiologic data: door-to-door studies Description of methods US Japan European markets Results Current prevalent cases and future trends Discussion Strengths and limits of Datamonitor's epidemiologic projections Conclusions 3. MARKET OVERVIEW Key findings Market definition for this report Seven major markets Current and future market overview The Japan and the five major European markets are expected to drive growth Newer classes drove historical growth Generics to stifle long-term growth Undifferentiated pipeline therapies will struggle to compete with existing brands and generics US Current and future market overview Japan Current and future market overview Five major EU markets Current and future market overview France Current and future market assessment Germany Current and future market assessment Italy Current and future market assessment Spain Current and future market assessment UK Current and future market assessment Rest of the world snapshot Current market assessment Rest of the world accounts for a third of Parkinson's disease prescription by volume Patient acquisition process Introduction Trigger point 1: dopaminergics Trigger point 2: dopamine agonists Trigger point 3: catechol-O-methyltransferase inhibitors Trigger point 4: monoamine oxidase inhibitors ther treatments 4. BRAND DYNAMICS Key findings verview of competitive landscape Current brand dynamics Generic entry will cause market leaders to lose status during the forecast period Drivers of brand choice Ability to control motor symptoms Cost Side-effect profile Patient convenience Potential neuroprotective properties US formulary tier status for leading brands Mirapex and Mirapex ER (pramipexole; Drug overview Drug profile Product positioning Dopamine agonists move from adjunctive to first-line therapy SWOT analysis for Parkinson's disease Brand forecast to 2019 Requip and Requip XL (ropinirole; Drug overview Drug profile Product positioning Full Table of Contents is available at: -- http://www.fastmr.com/ About Datamonitor The Datamonitor Group is a world-leading provider of premium global business information, delivering independent data, analysis and opinion across the Automotive, Consumer Markets, Energy & Utilities, Financial Services, Logistics & Express, Pharmaceutical & Healthcare, Retail, Technology and Telecoms industries. Datamonitor's market intelligence products and services ensure that you will achieve your desired commercial goals by giving you the insight you need to best respond to your competitive environment. View more research from Datamonitor at http://www.fastmr.com/ About Fast Market Research Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156. # # # Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available. End
Account Email Address Account Phone Number Disclaimer Report Abuse
|
|